All In Biotech

Drug Trial Radar · NCT05279391

Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19

Combined Administration of Inhaled DNase, Baricitinib and Tocilizumab as Rescue Treatment in Severe COVID-19 Patients

Last checked: Nov 20, 2026Latest source record: Mar 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

150

Planned (sponsor's estimate)

Start

Oct 25, 2020

Primary completion

Nov 30, 2021

Study completion Dec 31, 2023

Sponsor

Lead sponsor
Democritus University of ThraceAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In patients with COVID-19, severe hypoxemic respiratory failure (SRF) leading to invasive mechanical ventilation (IMV), raises the mortality rate substantially. Thus, the management of patients with SRF to avoid intubation and intensive care admission is a challenging and crucial issue. This study describes, as rescue/compassionate treatment, a therapeutic protocol based on the multi-mechanistic nature of severe COVID-19, using the combination of inhaled DNase, Baricitinib and Tocilizumab on top of standard of care (SOC) consisting of heparin and dexamethasone. COVID-19 patients with SRF who were treated with SOC, SOC plus Anakinra (ANA), and SOC plus Tocilizumab (TOCI) will be studied as comparators. Primary endpoint will be the reduction of the in-hospital mortality rate, whereas secondary endpoints concern intubation rate, days of hospitalization and overall survival as derived from the last follow-up visit, either in-office or remote. This is a non-randomized, open-label, study, conducted in the First Department of Internal Medicine, University Hospital of Alexandroupolis, Greece.

Conditions

  • COVID-19 Severe Respiratory Failure

Interventions

  • DexamethasoneDrug

    Dexamethasone 6-8 mg once daily

  • Low molecular weight heparinDrug

    Therapeutic doses of LMWH (e.g. Tinzaparin 175IU/kg)

  • Anakinra 100Mg/0.67Ml Inj SyringeDrug

    IV administration of Anakinra 200 mg/twice daily for 3-6 days, then 100 mg/twice daily, for up to 10 days in total.

  • TocilizumabDrug

    IV administration of Tocilizumab as a single dose of 8mg/kg

  • BaricitinibDrug

    4 mg per os once daily, for up to 14 days (2 mg if GFR: 30 to \<60 ml/min/1.73 m2)

  • Dornase Alfa Inhalant ProductDrug

    Inh. 2,500 U/twice daily, for up to 14 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. In-hospital mortality rateTime frame: Through study completion, an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital of Alexandroupolis

    Alexandroupoli, Evros, Greece · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.